PolyPeptide
ActiveSummary
PolyPeptide has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €103.8m and a net result of €7.2m. Equity is growing by about 4% per year across the filed financial years. Its solvency ranks better than 29% of 88 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Directors
Directors
1 director, no change since 2023
Board 1
Polypeptide Laboratories Holding (PPL) AB
CurrentSole director · since 17-05-2023 · Legal entity · permanent representative: Jens FRICKE
8 not recently confirmed
Still in office according to the deeds, but no deed of the last six years confirms the mandate. Mandates like this have often ended since, in a deed we have not read yet.
Stefan Stoffel
Not recently confirmedDirector · since 18-05-2010
Toralf Haag
Not recently confirmedDirector · since 17-05-2011
Abraham Arjen Vermeer
Not recently confirmedDirector · since 16-01-2012
Peter Nilsson
Not recently confirmedDirector · since 03-01-2017
El-Djouhar Alexandra Rekai
Not recently confirmedDirector
Geneviève De Bue
Not recently confirmedDirector
Mireille Colette B. Leclercq
Not recently confirmedDirector
Serge Marie J Doris
Not recently confirmedDirector
Day-to-day management 5
Alain Scarso
Not recently confirmedDaily management delegate · since 10-02-2006
Stéphane Mischler
Not recently confirmedDaily management delegate · since 10-02-2006
Bert Irma V Variroye
Not recently confirmedDirecteur général adjoint · since 30-04-2013
Frédérique Marie Vogeleiser ep. Mutterer
Not recently confirmedDirecteur général · since 30-04-2013
Frédérique Vogeleisen
Not recently confirmedDélégué à la gestion journalière / directeur général · since 01-05-2013
Permanent representatives 1
Jens FRICKE
CurrentPermanent representative · since 17-05-2023 · for Polypeptide Laboratories Holding (PPL) AB
Statutory auditor 1
BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
CurrentStatutory auditor · since 15-05-2018 · permanent representative: Rodrigo ABELS
Other functions 5
Patrick Loosen
Not recently confirmedMandataire spécial · since 19-05-2011
Eugénia Tsirimikos
Not recently confirmedMandataire · since 26-03-2014
M. Serge Doris
Not recently confirmedMandataire · since 26-03-2014
Mireille Leclercq
Not recently confirmedMandataire · since 26-03-2014
Mme Gerieviève De Bue
Not recently confirmedMandataire · since 26-03-2014
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ.
See the directors and other office holders in the KBO →
Mandate history
47 people since 2006, 20 in office
- Board
- Day-to-day management
- Statutory auditor
- Other function
- not recently confirmed
- began earlier
| Name | Functions and periods |
|---|---|
| Polypeptide Laboratories Holding (PPL) AB |
|
| BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES |
|
| Stefan Stoffel |
|
| Toralf Haag |
|
| Abraham Arjen Vermeer |
|
| El-Djouhar Alexandra Rekai |
|
| Geneviève De Bue |
|
| Mireille Colette B. Leclercq |
|
| Serge Marie J Doris |
|
| Peter Nilsson |
|
| Alain Scarso |
|
| Stéphane Mischler |
|
| Bert Irma V Variroye |
|
| Frédérique Marie Vogeleiser ep. Mutterer |
|
| Frédérique Vogeleisen |
|
| Patrick Loosen |
|
| Eugénia Tsirimikos |
|
| M. Serge Doris |
|
| Mireille Leclercq |
|
| Mme Gerieviève De Bue |
|
| Jan Fuhr MILLER |
|
| Jens FRICKE |
|
| Vincenzo MANCUSO |
|
| Raymond DE VRÉ |
|
| Daniel LASANOW |
|
| Jane Salik |
|
| Lars-Göran Peter Nilsson |
|
| KPMG Réviseurs d'Entreprises SC SCRL |
|
| Alain Marlier |
|
| Christian Cromlin |
|
| Klynveld Peat Marwick Goerdeler - KPMG SCRL |
|
| Bert Vanroye |
|
| Frédérique Marie Vogeleisen |
|
| Daniel Blättler |
|
| Rodolfo Jose Savitzky |
|
| Stefan Heinz Stoffel |
|
| Toralf Andrew Haag |
|
| Klynveld Peat Marwick Goedeler - KPMG SCRL |
|
| Stephan Kutzer |
|
| Arjen Vermeer |
|
| James Leresche |
|
| Laurent Demoisy |
|
| Olivier Ludemann-Hombourger |
|
| Pascal Brouyère |
|
| Uwe Boehlke |
|
| Seppe De Gelas |
|
| Lukas Utiger |
|
Owners and capital
Owners
2 ownersChain of control
- Polypeptide Group AGCH
- Polypeptide Laboratories Holding (PPL) ABSE
- PolyPeptide
Highest known parent: Polypeptide Group AG (Switzerland). The sources do not say who stands above it.
Owners 2
- Polypeptide Laboratories Holding (PPL) ABSEparentSourceown accounts 2025100%
- Polypeptide Group AGCHconsolidating parentconsolidates
According to the 2025 annual accounts of PolyPeptide and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
Shareholders according to the deeds
After the capital increase
act of 29-08-2007 ↗
- Lonza AG
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.
Capital over the years
- 29-12-2021 Capital stated in the deed · €40,000,000 · 40,000 shares
- 24-01-2013 Capital increase of €63,800,000 · to €103,800,000 · in kind
- 24-01-2013 Capital reduction of €63,800,000 · to €40,000,000 · to absorb losses
- 29-08-2007 Capital increase of €20,000,000 · to €40,000,000 · 20,000 new shares · in kind